Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy

IF 2.7 4区 医学 Q2 HEMATOLOGY Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-03-01 Epub Date: 2024-10-11 DOI:10.1016/j.clml.2024.10.005
Frida Bugge Askeland , Hege M. Frøen , Nils Bolstad , Per Medbøe Thorsby , Fredrik Schjesvold , Anne Cathrine Parelius Wammer , Ivar Følling , Geir E. Tjønnfjord
{"title":"Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy","authors":"Frida Bugge Askeland ,&nbsp;Hege M. Frøen ,&nbsp;Nils Bolstad ,&nbsp;Per Medbøe Thorsby ,&nbsp;Fredrik Schjesvold ,&nbsp;Anne Cathrine Parelius Wammer ,&nbsp;Ivar Følling ,&nbsp;Geir E. Tjønnfjord","doi":"10.1016/j.clml.2024.10.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Monoclonal insulin autoimmune syndrome (IAS) is a very rare disease characterized by severe attacks of hypoglycemia caused by circulating anti-insulin antibodies produced by a B-cell clone, usually clonal plasma cells.</div></div><div><h3>Method</h3><div>We present 2 female Norwegian patients with monoclonal IAS. The anti-insulin antibodies were quantified by immune precipitation and characterized using a 3-step manual in-house assay. Both patients received plasma cell directed therapy.</div></div><div><h3>Result</h3><div>The first patient received plasma cell directed therapy for a time-limited period and achieved a sustained clinical remission without detectable anti-insulin antibodies. The second patient receives continuous plasma cell directed therapy and is in clinical remission with low values of detectable anti-insulin antibodies.</div></div><div><h3>Conclusion</h3><div>Plasma cell directed therapy was effective and safe in our 2 cases of monoclonal IAS. We recommend considering plasma cell directed therapy for these patients.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 3","pages":"Pages e127-e130"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024023607","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Monoclonal insulin autoimmune syndrome (IAS) is a very rare disease characterized by severe attacks of hypoglycemia caused by circulating anti-insulin antibodies produced by a B-cell clone, usually clonal plasma cells.

Method

We present 2 female Norwegian patients with monoclonal IAS. The anti-insulin antibodies were quantified by immune precipitation and characterized using a 3-step manual in-house assay. Both patients received plasma cell directed therapy.

Result

The first patient received plasma cell directed therapy for a time-limited period and achieved a sustained clinical remission without detectable anti-insulin antibodies. The second patient receives continuous plasma cell directed therapy and is in clinical remission with low values of detectable anti-insulin antibodies.

Conclusion

Plasma cell directed therapy was effective and safe in our 2 cases of monoclonal IAS. We recommend considering plasma cell directed therapy for these patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用血浆细胞导向疗法成功治疗单克隆胰岛素自身免疫综合征
背景:单克隆胰岛素自身免疫综合征(IAS单克隆胰岛素自身免疫综合征(IAS)是一种非常罕见的疾病,其特征是由B细胞克隆(通常是克隆浆细胞)产生的循环抗胰岛素抗体导致的严重低血糖发作:我们介绍了两名患有单克隆 IAS 的挪威女性患者。抗胰岛素抗体通过免疫沉淀法进行定量,并采用内部三步人工检测法进行鉴定。两名患者均接受了浆细胞导向疗法:结果:第一名患者接受了有时限的血浆细胞导向疗法,并获得了持续的临床缓解,没有检测到抗胰岛素抗体。第二名患者接受了持续的血浆细胞导向疗法,临床症状得到缓解,检测到的抗胰岛素抗体值较低:结论:浆细胞导向疗法对我们的 2 例单克隆 IAS 患者有效且安全。我们建议考虑对这些患者进行浆细胞导向疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.70
自引率
3.70%
发文量
1606
审稿时长
26 days
期刊介绍: Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
期刊最新文献
Editorial Board Table of Contents Prognostic Impact of the Level of Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation on Pediatric Patients With Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1